Compare · OBIO vs RLX
OBIO vs RLX
Side-by-side comparison of Orchestra BioMed Holdings Inc. (OBIO) and RLX Technology Inc. (RLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OBIO and RLX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RLX is the larger of the two at $2.09B, about 6.2x OBIO ($339.0M).
- Over the past year, OBIO is up 55.8% and RLX is down 28.0% - OBIO leads by 83.9 points.
- OBIO has hit the wire 4 times in the past 4 weeks while RLX has been quiet.
- OBIO has more recent analyst coverage (10 ratings vs 2 for RLX).
PerformanceOBIO+55.83%RLX-28.03%
2025-10-16+0.00%2026-10-15
- Company
- Orchestra BioMed Holdings Inc.
- RLX Technology Inc.
- Price
- $5.75+1.95%
- $1.72+0.58%
- Market cap
- $339.0M
- $2.09B
- 1M return
- -4.49%
- -1.43%
- 1Y return
- +55.83%
- -28.03%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- 2021
- News (4w)
- 4
- 0
- Recent ratings
- 10
- 2
RLX
RLX Technology Inc.
RLX Technology Inc., together with its subsidiaries, researchers, develops, manufactures, distributes, and sells e-vapor products in the People's Republic of China. It serves RELX branded partner stores and other retail outlets through distributors. RLX Technology Inc. was founded in 2018 and is based in Beijing, China.
Latest OBIO
- Officer Sherman Darren sold $95,400 worth of shares (15,000 units at $6.36) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,119,402 units (SEC Form 4)
- SEC Form 144 filed by Orchestra BioMed Holdings Inc.
- Orchestra BioMed Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
- Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
- Officer Hochman David P covered exercise/tax liability with 6,566 shares, decreasing direct ownership by 0.31% to 1,067,463 units (SEC Form 4) (tax withholding)
- Orchestra BioMed upgraded by BTIG Research with a new price target
- Orchestra BioMed Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Officer Hochman David P bought $47,900 worth of shares (10,000 units at $4.79), increasing direct ownership by 0.94% to 1,070,746 units (SEC Form 4)
- Officer Sherman Darren sold $74,100 worth of shares (15,000 units at $4.94) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,134,402 units (SEC Form 4)
Latest RLX
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited Second Quarter 2026 Financial Results
- RLX Technology to Report Second Quarter 2026 Financial Results on August 14, 2026
- SEC Form 4 filed by Chief Financial Officer Lu Chao
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited First Quarter 2026 Financial Results
- RLX Technology to Report First Quarter 2026 Financial Results on May 20, 2026
- RLX Technology Files 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by RLX Technology Inc.
- SEC Form 3 filed by new insider Wang Ying Kate